bluebird bio Inc (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,500 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $139.80, for a total value of $209,700.00. Following the sale, the insider now owns 42,421 shares of the company’s stock, valued at approximately $5,930,455.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
NASDAQ:BLUE opened at $151.57 on Friday. bluebird bio Inc has a 52 week low of $87.49 and a 52 week high of $220.20. The firm has a market cap of $8.33 billion, a price-to-earnings ratio of -14.19 and a beta of 2.64.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, beating the consensus estimate of ($2.83) by $0.11. The firm had revenue of $19.20 million for the quarter, compared to analyst estimates of $9.06 million. bluebird bio had a negative return on equity of 32.15% and a negative net margin of 1,018.02%. bluebird bio’s revenue for the quarter was up 357.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.52) earnings per share. Sell-side analysts predict that bluebird bio Inc will post -11.67 EPS for the current fiscal year.
Several research firms recently issued reports on BLUE. Svb Leerink cut bluebird bio from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Leerink Swann lowered bluebird bio from an “outperform” rating to a “market perform” rating and set a $150.00 price target for the company. in a research note on Tuesday, March 5th. They noted that the move was a valuation call. ValuEngine raised bluebird bio from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Cowen initiated coverage on bluebird bio in a research note on Tuesday, February 26th. They set an “outperform” rating and a $149.91 price target for the company. Finally, SunTrust Banks dropped their price target on bluebird bio to $184.00 and set a “buy” rating for the company in a research note on Monday, February 25th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. bluebird bio presently has an average rating of “Buy” and a consensus target price of $168.12.
COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) Insider Sells $209,700.00 in Stock” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4222951/bluebird-bio-inc-blue-insider-sells-209700-00-in-stock.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.